ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO06-SA

GIGA-Kids: Genomics of IgA-Related Diseases in Kids

Session Information

  • Informational Posters - III
    November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Genetic Diseases of the Kidneys

Authors

  • Balderes, Olivia, Columbia University, New York, New York, United States
  • Kiryluk, Krzysztof, Columbia University, New York, New York, United States
  • Smoyer, William E., Nationwide Children's Hospital, Columbus, Ohio, United States
  • Nelson, Raoul D., University of Utah, Salt Lake City, Utah, United States
  • Gharavi, Ali G., Columbia University, New York, New York, United States
  • Wenderfer, Scott E., Baylor College of Medicine, Houston, Texas, United States
  • Lin, Fangming, Columbia University College of Physicians & Surgeons, New York, New York, United States
  • Chishti, Aftab S., University of Kentucky, Lexington, Kentucky, United States
  • Vasylyeva, Tetyana L., Texas Tech, Amarillo, Texas, United States
  • Flynn, Joseph T., Seattle Children's Hospital, Seattle, Washington, United States
  • Akchurin, Oleh M., Weill Cornell College of Medicine, New York, New York, United States
  • Al-Akash, Samhar I., Driscoll Children's Hospital, Corpus Christi, Texas, United States
  • Xiao, Nianzhou, Children's Hospital of Richmond, VCU, Richmond, Virginia, United States
  • Dharnidharka, Vikas R., Washington University School of Medicine, St Louis, Missouri, United States
  • Mason, Sherene, Connecticut Children's Medical Center, New Haven, Connecticut, United States
  • Bou Matar, Raed, Cleveland Clinic, Cleveland, Ohio, United States
  • Hastings, Margaret Colleen, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Ranch, Daniel, UT Health San Antonio, San Antonio, Texas, United States
  • Erkan, Elif, Children's Hospital of Cincinnati, CIncinnati, Ohio, United States
  • Iorember, Franca M., Phoenix Children's Hospital, Scottsdale, Arizona, United States
  • Selewski, David T., Medical University of South Carolina, Mount Pleasant, South Carolina, United States
  • Hidalgo, Guillermo, Eastern Carolina University, Greenville, North Carolina, United States
  • Rheault, Michelle N., University of Minnesota, Minneapolis, Minnesota, United States
Description

IgA nephropathy (IgAN) represents the leading cause of kidney failure among young adults and is the most prevalent form of primary glomerulonephritis worldwide. Prior genetic studies in adults have discovered 20 distinct GWAS susceptibility loci and defined IgAN as an autoimmune trait with a complex genetic architecture. There is also a strong inverse relationship between the burden of GWAS risk alleles and the age of IgAN onset. These observations suggest that pediatric patients are likely enriched for genetic causes of disease, yet pediatric cohorts are not presently available for genetic studies.

The GIGA-Kids Study (Genomics of IgA-related disorders in kids, www.gigakids.org) is a multicenter collaborative study that aims to recruit over 1,000 North American children with IgAN or Henoch-Schönlein purpura (with or without nephritis). There are 27 sites nationwide actively recruiting patients. This study represents one of the largest recruitment efforts in the field of rare pediatric kidney disease. The study is in its fifth year of activity and has recruited over 460 patients in the U.S. alone. As of June 2017, the North American GIGA-kids cohort is the largest pediatric IgAN and HSP/N cohort to date.

Any patients diagnosed before the age of 21 (but without active HBV, HCV, HIV, autoimmune or liver disease), are eligible to participate. All study participants undergo genome–wide SNP genotyping, whole exome sequencing, and blood RNA-sequencing. The GIGA-Europe Network, which mirrors the North American study, aims to recruit additional 1,000 European patients across major nephrology centers in Italy, France, Poland, Sweden, the Netherlands, Croatia, Czech Republic, Hungary, Turkey, and the UK. Both the GIGA-kids and GIGA-Europe networks remain open to new collaborating centers. The GIGA network is sponsored by the IgA Nephropathy Foundation of America and the Midwest Pediatric Nephrology Consortium (MWPNC).

Funding

  • IgA Nephropathy Foundation of America (Non-profit NGO).